Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: Arch Pathol Lab Med. 2015 Jun 5;139(11):1334–1348. doi: 10.5858/arpa.2014-0498-RA

Figure 1. Signaling pathways in HNSCC invasion involving the EGFR.

Figure 1.

Epidermal growth factor receptor (EGFR), activated by EGFR ligands, can activate ERK/AP1, PI3K/Akt, or Src activity, which all lead to increased invasion in head and neck cancer. EGFR can be cross-activated by GCPRs, whose downstream signaling leads to the release of EGFR ligands from their transmembrane precursors through activity by the ADAM family of proteases.